Biotechnology & Drugs Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotechnology & Drugs

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: 2MAR$ who started this subject	2/28/2004 4:57:39 PM
From: 2MAR$	Read Replies (1) of 232

1/12 $47-$40-$41 Celgene plunges in reaction to guidance (CELG) 44.69 -1.92: Co announces it provided 2004 guidance at the JP Morgan Annual Healthcare Conference; co sees 2004 EPS of $0.40-$0.50 (consensus $0.60) on $360-$380 mln in sales (consensus $376.1 mln). CELG downgraded at JP Morgan 42.59: JP Morgan downgrades Celgene (CELG) to Neutral from Overweight, citing the lack of significant Revimid catalysts in 1H04, decelerating Thalomid prescription growth, and a relatively robust valuation. 29-Jan-04 07:35 ET In Play Celgene misses by $0.01, ex items, guides Y04 in line (CELG) 41.51: Reports Q4 (Dec) earnings of $0.05 per diluted share, excluding $0.01 gain on sale of chiral assets, $0.01 worse than the Reuters Research consensus of $0.06; revenues rose 117.2% year/year to $80.8 mln vs the $78.6 mln consensus. Co also guides Y04, sees EPS of $0.40-0.50, vs the R.R. consensus of $0.50, and revenues of $360-380 mln, vs an estimate of $375.8 mln

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next